News UCB

Equities

UCB

BE0003739530

Market Closed - Euronext Bruxelles Other stock markets 11:35:04 2024-04-23 am EDT			5-day change	1st Jan Change
121.8 ^EUR	-0.20%		+2.01%	+54.31%

Apr. 11	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
Apr. 11	UCB : Berenberg, Buy, raises its price target	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa	Apr. 22	PU
UCB : FINTEPLA▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)	Apr. 17	PU
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting	Apr. 15	AQ
UCB : Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY▼ (romosozumab) can help to close the treatment gap in osteoporosi	Apr. 12	PU
UCB : presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting	Apr. 12	PU
Berenberg Reiterates UCB's Purchase Rating, Raises PT	Apr. 11	MT
UCB : Berenberg, Buy, raises its price target	Apr. 11	CF
UCB : Acquisition of own shares - 2024	Apr. 06	PU
UCB: new indication in sight for Bimzelx in the USA	Apr. 04	CF
UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx	Apr. 04	CI
UCB : FDA Accepts Supplemental Biologics License Applications for BIMZELX (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations	Apr. 04	PU
Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees	Apr. 01	AQ
UCB : Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees	Mar. 29	PU
UCB : receives positive CHMP opinion for BIMZELX▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa	Mar. 22	PU
UCB Convening Notice to the General Meeting of the Shareholders 2024	Mar. 22	GL
UCB : announces changes on Board of Directors	Mar. 15	PU
UCB : Financial Reporting Document	Mar. 13	PU
UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies	Mar. 08	CI
UCB : UCB all set to reach new highs	Mar. 08
UCB Secures British Regulatory Nod for Generalized Myasthenia Gravis Treatment	Mar. 07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

UCB : UCB all set to reach new highs

March 08, 2024 at 11:10 am EST